GlassScriptPhysician profile
Yanyan Wang
NPI 1043806045
$3,828.14
in general payments reported to CMS, 2019-2025
25 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $378 · 2024: $1,576 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.64 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.66 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $679.64 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $324.97 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $277.96 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $272.26 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $195.79 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $161.83 | 2024-2025 | Auvelity |
| Lundbeck LLC | $143.22 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $143.16 | 2023 | |
| Indivior INC. | $132.58 | 2023-2024 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $127.41 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $120.72 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.70 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $102.35 | 2024-2025 | Trintellix |
| Corium, LLC | $71.46 | 2024 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $53.64 | 2024-2025 | Xelstrym |
| Luye Pharma (USA) LTD. | $45.63 | 2025 | Erzofri Extended-Release |
| Neos Therapeutics, LP | $30.26 | 2024 | Adzenys Xr-Odt |
| Braeburn INC. | $27.58 | 2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $24.97 | 2025 | Jornay Pm |
| Tempus Ai, INC | $20.39 | 2024 | |
| Sage Therapeutics, LLC | $19.72 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $19.72 | 2025 | Qelbree |
| Validus Pharmaceuticals LLC | $18.50 | 2025 | Equetro, Raldesy |
| Owp Pharmaceuticals, INC. | $17.02 | 2024 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanyan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.